A large national comparative study of clinicopathological features and long-term survivals between esophageal gastrointestinal stromal tumor and leiomyosarcoma

Basem Azab, Francisco Igor Macedo, Samuel H. Cass, Caroline Ripat, Syed S. Razi, Omar Picado, Dido Franceschi, Alan S. Livingstone, Danny Yakoub

Research output: Contribution to journalArticle

Abstract

Background: Esophageal gastrointestinal stromal tumors (E-GIST) and leiomyosarcoma (E-LMS) are rare tumors. Previous studies are limited to small number of patients. We sought to study these two tumors using a large national database. Methods: The National Cancer Data Base 2004–2014 was queried for patients with E-GIST and E-LMS. The primary outcome was overall survival (OS). Univariate and multivariable Cox regression models were used to investigate OS predictors. Results: We found 141 E-GIST and 38 E-LMS patients, with esophagectomy and systemic treatment rate of 55% and 49% for E-GIST and 50% and 26% for E-LMS. The 5-year OS of E-GIST and E-LMS were 62% and 23%, respectively, p < 0.001. In multivariable analysis, young age, tumor <10 cm, esophagectomy, and E-GIST were associated with superior OS. There was a higher median and mean OS with neoadjuvant vs. upfront surgery for E-GIST group (98 and 111 vs 79 and 80 months). Conclusion: E E-GIST has superior OS compared to E-LMS. Esophagectomy is the cornerstone treatment modality. Further studies are needed to evaluate the role of neoadjuvant therapy in E-GIST patients.

Original languageEnglish (US)
Pages (from-to)323-328
Number of pages6
JournalAmerican Journal of Surgery
Volume218
Issue number2
DOIs
StatePublished - Aug 1 2019

Fingerprint

Gastrointestinal Stromal Tumors
Leiomyosarcoma
Survival
Esophagectomy
Neoplasms
Databases
Neoadjuvant Therapy
Proportional Hazards Models

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

A large national comparative study of clinicopathological features and long-term survivals between esophageal gastrointestinal stromal tumor and leiomyosarcoma. / Azab, Basem; Macedo, Francisco Igor; Cass, Samuel H.; Ripat, Caroline; Razi, Syed S.; Picado, Omar; Franceschi, Dido; Livingstone, Alan S.; Yakoub, Danny.

In: American Journal of Surgery, Vol. 218, No. 2, 01.08.2019, p. 323-328.

Research output: Contribution to journalArticle

Azab, Basem ; Macedo, Francisco Igor ; Cass, Samuel H. ; Ripat, Caroline ; Razi, Syed S. ; Picado, Omar ; Franceschi, Dido ; Livingstone, Alan S. ; Yakoub, Danny. / A large national comparative study of clinicopathological features and long-term survivals between esophageal gastrointestinal stromal tumor and leiomyosarcoma. In: American Journal of Surgery. 2019 ; Vol. 218, No. 2. pp. 323-328.
@article{3b6661bf24174174bd6b8c1bbd43481a,
title = "A large national comparative study of clinicopathological features and long-term survivals between esophageal gastrointestinal stromal tumor and leiomyosarcoma",
abstract = "Background: Esophageal gastrointestinal stromal tumors (E-GIST) and leiomyosarcoma (E-LMS) are rare tumors. Previous studies are limited to small number of patients. We sought to study these two tumors using a large national database. Methods: The National Cancer Data Base 2004–2014 was queried for patients with E-GIST and E-LMS. The primary outcome was overall survival (OS). Univariate and multivariable Cox regression models were used to investigate OS predictors. Results: We found 141 E-GIST and 38 E-LMS patients, with esophagectomy and systemic treatment rate of 55{\%} and 49{\%} for E-GIST and 50{\%} and 26{\%} for E-LMS. The 5-year OS of E-GIST and E-LMS were 62{\%} and 23{\%}, respectively, p < 0.001. In multivariable analysis, young age, tumor <10 cm, esophagectomy, and E-GIST were associated with superior OS. There was a higher median and mean OS with neoadjuvant vs. upfront surgery for E-GIST group (98 and 111 vs 79 and 80 months). Conclusion: E E-GIST has superior OS compared to E-LMS. Esophagectomy is the cornerstone treatment modality. Further studies are needed to evaluate the role of neoadjuvant therapy in E-GIST patients.",
author = "Basem Azab and Macedo, {Francisco Igor} and Cass, {Samuel H.} and Caroline Ripat and Razi, {Syed S.} and Omar Picado and Dido Franceschi and Livingstone, {Alan S.} and Danny Yakoub",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.amjsurg.2018.10.046",
language = "English (US)",
volume = "218",
pages = "323--328",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - A large national comparative study of clinicopathological features and long-term survivals between esophageal gastrointestinal stromal tumor and leiomyosarcoma

AU - Azab, Basem

AU - Macedo, Francisco Igor

AU - Cass, Samuel H.

AU - Ripat, Caroline

AU - Razi, Syed S.

AU - Picado, Omar

AU - Franceschi, Dido

AU - Livingstone, Alan S.

AU - Yakoub, Danny

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: Esophageal gastrointestinal stromal tumors (E-GIST) and leiomyosarcoma (E-LMS) are rare tumors. Previous studies are limited to small number of patients. We sought to study these two tumors using a large national database. Methods: The National Cancer Data Base 2004–2014 was queried for patients with E-GIST and E-LMS. The primary outcome was overall survival (OS). Univariate and multivariable Cox regression models were used to investigate OS predictors. Results: We found 141 E-GIST and 38 E-LMS patients, with esophagectomy and systemic treatment rate of 55% and 49% for E-GIST and 50% and 26% for E-LMS. The 5-year OS of E-GIST and E-LMS were 62% and 23%, respectively, p < 0.001. In multivariable analysis, young age, tumor <10 cm, esophagectomy, and E-GIST were associated with superior OS. There was a higher median and mean OS with neoadjuvant vs. upfront surgery for E-GIST group (98 and 111 vs 79 and 80 months). Conclusion: E E-GIST has superior OS compared to E-LMS. Esophagectomy is the cornerstone treatment modality. Further studies are needed to evaluate the role of neoadjuvant therapy in E-GIST patients.

AB - Background: Esophageal gastrointestinal stromal tumors (E-GIST) and leiomyosarcoma (E-LMS) are rare tumors. Previous studies are limited to small number of patients. We sought to study these two tumors using a large national database. Methods: The National Cancer Data Base 2004–2014 was queried for patients with E-GIST and E-LMS. The primary outcome was overall survival (OS). Univariate and multivariable Cox regression models were used to investigate OS predictors. Results: We found 141 E-GIST and 38 E-LMS patients, with esophagectomy and systemic treatment rate of 55% and 49% for E-GIST and 50% and 26% for E-LMS. The 5-year OS of E-GIST and E-LMS were 62% and 23%, respectively, p < 0.001. In multivariable analysis, young age, tumor <10 cm, esophagectomy, and E-GIST were associated with superior OS. There was a higher median and mean OS with neoadjuvant vs. upfront surgery for E-GIST group (98 and 111 vs 79 and 80 months). Conclusion: E E-GIST has superior OS compared to E-LMS. Esophagectomy is the cornerstone treatment modality. Further studies are needed to evaluate the role of neoadjuvant therapy in E-GIST patients.

UR - http://www.scopus.com/inward/record.url?scp=85056869630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056869630&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2018.10.046

DO - 10.1016/j.amjsurg.2018.10.046

M3 - Article

VL - 218

SP - 323

EP - 328

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 2

ER -